

# Emerging Molecular Assays for Detection and Characterization of Respiratory Viruses

Wenjuan Wu, PhD<sup>a,c</sup>, Yi-Wei Tang, MD, PhD<sup>a,b,d,\*</sup>

## KEYWORDS

- Respiratory viruses • Quantum dots
- In vitro nucleic acid amplification • Multiplex • Pyrosequencing
- Padlock probes • Microarrays • Mass spectrometry

Rapid detection and identification of viral pathogens causing respiratory tract infections is critical for initiating antiviral therapy, avoiding unnecessary antimicrobial therapy, preventing nosocomial spread, decreasing the duration of hospitalization, and reducing management costs. Molecular assays, which provide high sensitivity and specificity, short test turnaround time, and automatic, high-throughput batch processing, have played critical roles in rapid detection, screening, and identification of emerging respiratory viral pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and novel A/H1N1 influenza (Flu) virus.<sup>1–3</sup> The superiority of polymerase chain reaction (PCR), reverse transcription-PCR (RT-PCR), and other in vitro nucleic acid amplification assays over conventional methods for the diagnosis of respiratory viral infections has already been established.<sup>4,5</sup> This article describes several emerging molecular assays that have potential applications in the diagnosis and monitoring of respiratory viral infections.

## DIRECT NUCLEIC ACID DETECTION BY QUANTUM DOTS BIOSENSORS

Biosensors offer the possibility of real-time monitoring, and the deployment of these devices in the field would provide a means for prompt etiologic diagnosis. All

---

<sup>a</sup> Department of Pathology, Vanderbilt University Medical Center, 4605 TVC, 1161 21st South Avenue, Nashville, TN, USA

<sup>b</sup> Department of Medicine, Vanderbilt University Medical Center, 4605 TVC, 1161 21st South Avenue, Nashville, TN, USA

<sup>c</sup> Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Shanghai, 201508, People's Republic of China

<sup>d</sup> Molecular Infectious Disease Laboratory, Vanderbilt University Hospital, 4605 TVC, Nashville, TN 37232-5310, USA

\* Corresponding author. Molecular Infectious Disease Laboratory, Vanderbilt University Hospital, 4605 TVC, Nashville, TN 37232-5310.

*E-mail address:* [yiwei.tang@vanderbilt.edu](mailto:yiwei.tang@vanderbilt.edu) (Y.W. Tang).

biosensors are essentially composed of a biologic recognition element or bioreceptor, which interacts with the analyte and responds in some manner that can be registered by a transducer. The bioreceptor is a crucial component, and its function is to impart selectivity so that the sensor responds only to a particular analyte or biomolecule of interest, hence avoiding interference from other substances. The transducer converts the microbial biorecognition event into an electrical signal detected using electrochemical, optical, or piezoelectric platforms.<sup>6,7</sup> A biosensor specifically targeting nucleic acids through hybridization is called a genosensor. Genosensors have been used to for direct, on-demand, and real-time detection and discrimination of microbial pathogens in clinical specimens. Malamud and colleagues<sup>8</sup> developed a group of genosensor-based assays to detect microbial pathogens in oral specimens for use in the diagnosis of multiple infectious diseases. A piezoelectric DNA biosensor to directly detect hepatitis B virus was developed based on the mass-transducing function of a quartz crystal microbalance and nucleic acid hybridization<sup>9</sup>; another hybridization-based amperometric biosensor, using osmium as an electrochemical indicator, was used for the detection and confirmation of virus-specific PCR products.<sup>10</sup> A generic semidisposable fluorescence biosensor was developed to directly detect dengue virus RNA.<sup>11</sup> A hybridization-based genosensor on gold film coupled with enzymatic electrochemical detection was designed to detect SARS-CoV RNA.<sup>12</sup>

Fluorescent semiconductor nanocrystals, known as quantum dots (Qdots), are colloidal particles consisting of a semiconductor core, a high band gap material shell, and typically an outer coating layer. The core-size-dependent photoluminescence with narrow emission bandwidths that span the visible spectrum and the broad adsorption spectra allow simultaneous excitation of mixed Qdot populations at a single wavelength. Qdots also exhibit several unique features: high quantum yield, high resistance to photodegradation, and better near-infrared emission.<sup>13,14</sup> The new generation of Qdots has far-reaching potential for the study of intracellular processes in broad fields, including diagnostics.<sup>14</sup> High-sensitivity bacterial detection using biotin-tagged phage and quantum-dot nanocomplexes has been described, which provides specific limits of detection at 10 bacterial cells/mL in 1 hour.<sup>15</sup> A bead-based microfluidic device was developed to achieve an ELISA with Qdots as the labeling fluorophore for virus detection.<sup>16</sup> Three groups have reported the use of Qdots conjugated to specific monoclonal antibodies to detect and identify the presence of respiratory syncytial virus (RSV) in a real-time manner, implying that Qdots may provide a method for early, rapid detection of RSV infections.<sup>17–19</sup> In addition to microbial pathogen antigen detection, positively charged compact Qdot-DNA complexes were described that can detect H5N1 Flu-A virus nucleic acids presented at concentrations as low as 200 nmol.<sup>20</sup> Simultaneous excitation of several emission-tunable Qdot populations can be combined with a pool of differentially labeled probes for multiplex target analysis.<sup>21,22</sup> Qdot-based techniques are under development to detect a panel of respiratory viruses, producing more efficient assays that require smaller quantities of target nucleic acids.

## AMPLIFICATION METHODS AND PLATFORMS

### *Loop-Mediated Isothermal Amplification*

First described by Notomi and colleagues<sup>23</sup> in 2000, loop-mediated isothermal amplification (LAMP) is a simple, rapid, and specific nucleic acid amplification method, which is characterized by the use of multiple primers specifically designed to recognize several distinct regions on the target gene. Amplification and detection of target genes can be completed in a single step, by incubating the mixture of samples, primers, DNA polymerase with strand displacement activity and substrates at

a constant temperature. Because amplification is isothermal, LAMP does not require special reagents or sophisticated temperature control devices. Because the increase in turbidity of the reaction mixture according to the production of precipitate correlates with the amount of DNA synthesized, real-time monitoring of the LAMP reaction can be achieved by turbidity measurement.<sup>24</sup> With a detection limit of about one to two copies, LAMP is capable of detecting the presence of pathogenic agents earlier than PCR if the gene copy number is low.<sup>25</sup>

LAMP has successfully been applied to the rapid and real-time detection of several emerging and reemerging human pathogens, including West Nile virus, dengue virus, Japanese encephalitis virus, monkey pox virus, Rift Valley virus, SARS-CoV, Chikungunya virus, and noroviruses.<sup>25–28</sup> Poon and colleagues<sup>29</sup> described the use of an RT-LAMP to detect Flu-A viruses covering H1 to H3. Another similar RT-LAMP assay was described more recently that detects Flu-A virus H1 and H3 subtype strains and Flu-B virus strains.<sup>30</sup> At a limit of detection of 10 focus-forming units per mL, both assays can be completed within 3 hours, providing rapid and sensitive detection.<sup>29,30</sup> Two one-step RT-LAMP assays with analytical sensitivities of 0.01 to 0.1 plaque-forming units (pfu) per reaction were developed specifically for detection of highly pathogenic avian Flu-A (H5N1) viruses and validated using H5N1 viral strains isolated over the past 10 years and clinical specimens.<sup>31–33</sup> An RT-LAMP assay was reported to specifically detect the H9 subtype of avian Flu virus with a detection limit of 10 copies per reaction, 10-fold lower than that of RT-PCR.<sup>34</sup> In Japan, the LAMP assay was used to rapidly subtype Flu-A virus and confirm two cases of influenza in patients who had returned from Thailand.<sup>30</sup>

In addition to the detection and typing of Flu viruses, a subgroup-A/B-specific RT-LAMP assay was developed to amplify RSV to improve current diagnostic methods for RSV infections. The assay was validated using nasopharyngeal aspirates from children who had respiratory tract infections, and the results indicated that the RT-LAMP is more sensitive than viral isolation and antigen testing for RSV detection.<sup>35,36</sup> Several LAMP-based assays were reported for rapid detection of SARS-CoV with the advantages of rapid amplification, simple operation, and ease of detection.<sup>28,37</sup> LAMP-based assays have also been used to detect other respiratory viral pathogens, such as mumps,<sup>38,39</sup> measles,<sup>40</sup> and adenoviruses.<sup>41</sup> In comparison to conventional RT-PCR, RT-LAMP assays demonstrated 10- to 100-fold enhanced sensitivity, with a detection limit of 0.01 to 10 pfu of virus in most cases.

### **Multiplex Ligation-Dependent Probe Amplification**

---

Recently established in The Netherlands, multiplex ligation-dependent probe amplification (MLPA) makes use of both ligation and PCR.<sup>42</sup> Inventively modified from previously described ligation-dependent PCR assays,<sup>43,44</sup> the MLPA platform features greatly reduced probe concentrations and longer hybridization periods to generate conditions compatible with multiplex analysis. Each MLPA probe consists of a pair of oligonucleotides subject to ligation when hybridized to a target sequence, analogous to a padlock probe (see later discussion). One oligonucleotide consists of a 5' fluorescent label, a universal forward primer binding site, and a target-specific recognition sequence at the 3' end, whereas the other oligonucleotide consists of a target-specific recognition sequence at the 5' end, a nonspecific stretch of DNA of defined length ("stuffer" sequence), and a universal reverse primer binding site at the 3' end. Each MLPA assay is divided into three basic steps: (1) annealing of probes to their target sequences, (2) ligation of the probes, and (3) PCR amplification of ligated probes using universal primers. Multiplexing is achieved by varying the length of stuffer sequence for each unique set of probes used in the assay. Amplification

products are detected using high-resolution electrophoretic techniques, such as capillary electrophoresis, and it is claimed that this approach allows relative quantification.<sup>42</sup>

MLPA-based techniques have proved sufficiently sensitive, reproducible, and sequence specific for use in screening human DNA. Recent studies have use of the MLPA assay for the detection and identification of several pathogenic microorganisms, including rapid characterization of *Mycobacterium tuberculosis*,<sup>45</sup> and relative quantification of targeted bacterial species in oral microbiota.<sup>46</sup> Reijans and colleagues<sup>47</sup> described an MLPA technology-based RespiFinder assay to detect 15 respiratory viruses simultaneously in one reaction. In this case, the MLPA reaction was preceded by a preamplification step that ensured detection of both RNA and DNA viruses with the same specificity and sensitivity as individual monoplex real-time RT-PCR assays. The RespiFinder assay showed satisfactory specificity and perfect sensitivity for adenovirus, human metapneumovirus (hMPV), Flu-A, parainfluenza virus (PIV) types 1 and 3, rhinovirus (RhV), and RSV. Use of the RespiFinder assay resulted in a 24.5% increase in the diagnostic yield compared with cell culture. This assay is being extended to cover four additional bacterial pathogens that cause respiratory tract infections: *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Legionella pneumophila*, and *Bordetella pertussis*.

### ***Polymerase Chain Reaction Amplification Using Arbitrary Primers***

PCR amplification techniques using arbitrary primers, including arbitrarily primed (AP) PCR,<sup>48</sup> sequence-independent single-primer amplification (SISPA),<sup>49</sup> and randomly amplified polymorphic DNA (RAPD),<sup>50</sup> are generally based on the PCR amplification of random DNA segments with short primers (usually a single 1 of 10 nucleotides) containing arbitrary nucleotide sequences. RAPD-based assays have increasingly been used to type microorganisms, especially during clinical outbreaks.<sup>51</sup> The RAPD-PCR technique seems to be practical and efficient for routine use in high-resolution viral diversity studies by providing assemblage comparisons through fingerprinting, probing, or sequence information.<sup>52</sup> Similar techniques have been used to characterize the polymerase gene and genomic termini of Nipah virus<sup>53</sup> and avian Flu virus genome sequences.<sup>54</sup>

On the other hand, AP-PCR and SISPA-based assays have mainly been used for the discovery and characterization of novel and noncultivable viruses.<sup>55</sup> Because viral pathogens do not possess conserved, universal genes, such as 16S rRNA genes, SISPA was used in the early 1990s as a random PCR amplification strategy to amplify known and unknown viral genes, including those of hepatitis C virus, rotavirus, and norovirus.<sup>56–58</sup> The AP-PCR technique was used successfully to obtain sequence information on a novel hMPV after the virus was cultured.<sup>59</sup> Wang and colleagues<sup>60,61</sup> used a similar random amplification technique in conjunction with a long oligonucleotide pan-viral microarray to simultaneously screen and detect hundreds of viral pathogens. This system has successfully been used for the detection of a human PIV-4 strain associated with respiratory failure,<sup>62</sup> for identification of a novel gammaretrovirus in a patient who had prostate tumors,<sup>63</sup> for the diagnosis of a critical respiratory illness caused by hMPV,<sup>64</sup> and for the identification of cardiociruses related to Theiler murine encephalomyelitis virus in human infections.<sup>65</sup> Quan and colleagues<sup>66</sup> recently reported the use of a similar random amplification process followed by comprehensive microarray analysis (GreeneChipResp) to detect diverse respiratory viral pathogens and subtype Flu-A viruses.

A modified SISPA incorporating DNase treatment has recently been used to discover, identify, and characterize several novel bovine and human viral pathogens

directly from clinical samples.<sup>67–70</sup> The same technology has been used for the characterization of common epitopes in enterovirus (EnV),<sup>71</sup> identification of a novel human coronavirus,<sup>72</sup> detection of TT virus in stool samples collected during a gastroenteritis outbreak,<sup>73</sup> and discovery of novel unculturable viruses in specimens collected from patients presenting with fever of unknown origin.<sup>74,75</sup> Although PCR amplification using arbitrary primers has been an extremely powerful approach for screening and discovery of new or noncultivable viral pathogens directly from clinical specimens, subsequent identification and confirmation steps are hindered by a background of nonspecific random amplification products. Further development is thus required to optimize this technology for routine diagnostic use in molecular microbiology laboratories.

### **Target-Enriched Multiplexing Amplification**

---

Multiplex PCR was developed to use numerous primers within a single reaction tube to amplify nucleic acid fragments from different targets. Multiple sets of high-concentration primers in the conventional multiplex reaction often favor primer-dimer formation, however, resulting in nonspecific amplification. To meet the challenges of conventional multiplex PCR, Han and colleagues<sup>76</sup> developed target-enriched multiplexing (TEM)-PCR technology, which uses nested gene-specific primers at extremely low concentrations to enrich specific targets during early PCR cycles and relies on universal forward and reverse “superprimers” at high, but unequal, concentrations to achieve exponential asymmetric target amplification. TEM-PCR amplification has been reported for the detection, typing, and semiquantification of 25 human papillomaviruses,<sup>76</sup> detection and differentiation of a panel of respiratory bacterial pathogens,<sup>77–79</sup> detection and differentiation of 24 antituberculosis drug resistance-related mutations,<sup>80</sup> determination of antibiotic resistance and detection of toxin-encoding genes in *Staphylococcus aureus*,<sup>81</sup> screening and differentiation of methicillin-resistant *S aureus* and vancomycin-resistant enterococci,<sup>82</sup> and characterization and typing of Flu-A, including H5N1.<sup>83</sup>

Using TEM technology, the ResPlex II assay was developed to detect Flu-A, Flu-B, PIV-1, PIV-2, PIV-3, PIV-4, RSV, hMPV, RhV, EnV, and SARS-CoV in a single reaction.<sup>78,84,85</sup> When monoplex RT PCR is used for pathogen detection, the clinician often does not consider the possible presence of other pathogens when given a positive result. The multiplex approach offered by the ResPlex II system enhances diagnosis through detection of respiratory viral etiologic agents in cases in which their presence was unsuspected and an appropriate test consequently was not ordered by the clinician.<sup>85</sup> A recent study by Brunstein and colleagues<sup>84</sup> revealed that, using the ResPlex II kit covering 12 viral pathogens, 2.5% of specimens were coinfecting with two or three different viruses. (A low level of cross-reactivity between PIV-1 and PIV-3 was noticed using this assay.<sup>85</sup>) These coinfections are medically relevant, and effective treatment of severe respiratory tract infections will increasingly require diagnosis of all involved pathogens, as opposed to single-pathogen reporting.<sup>84</sup> The original ResPlex II system detects only RNA viruses, but adenoviruses, bocavirus, and four coronaviruses have been added to a recently released new version of ResPlex II. Preliminary data indicate that the overall sensitivity and specificity of ResPlex II v2.0 is comparable to that of the ResPlex II panel. A notable number of previously negative samples were found to be positive for one of the newly added bocavirus or coronavirus targets (John Brunstein, 2009; personal communication). A factor that could diminish the analytical and clinical performance of ResPlex II and ResPlex II v2.0 is the potential for false-positive results caused by carryover of PCR products using the Luminex platform.

**AMPLIFICATION PRODUCT DETECTION AND IDENTIFICATION*****Pyrosequencing***

Direct amplicon sequencing provides simple, rapid, and accurate means of detection and identification of amplification products. The need for robust, high-throughput methods to replace the elegant Sanger method, which was described more than 30 years ago,<sup>86</sup> has led to the development of several new principles. Ronaghi and colleagues<sup>87,88</sup> described in 1998 a pyrosequencing technique, a non-gel-based real-time approach to sequencing DNA by monitoring DNA polymerase activity. Pyrosequencing is based on enzymatic inorganic pyrophosphate release by DNA polymerase. This reaction is stoichiometric; the amount of light produced is proportional to the number of pyrophosphate molecules generated and, hence, the number of incorporated nucleotides. Unincorporated nucleotides are degraded with apyrase before the next nucleotide is added. In this way, sequence information on an interrogated region is generated quantitatively in real time. Although basic approaches to performing pyrosequencing remain the same, numerous commercial systems have been used widely to rapidly identify infectious agents and screen for antimicrobial drug resistance.<sup>89–91</sup> Multiplexed pyrosequencing involving the simultaneous extension of several primers hybridized to one or more target DNA templates<sup>92</sup> has gained broad acceptance in the fields of cytogenetics, pharmacogenetics, and medical genetics.<sup>71,93,94</sup>

Most applications of pyrosequencing in the identification and characterization of respiratory viruses have focused on Flu-A. Based on pyrosequencing technology, a rapid and highly informative diagnostic assay was reported for the detection of H5N1 Flu viruses<sup>95</sup>; sequencing of critical regions within the H5 virus was developed as a screening method during high volumes of H5N1 activity.<sup>95</sup> A real-time RT-PCR pyrosequencing assay was developed that combines restriction enzyme digestion and direct sequencing to screen and verify H5 Flu infections in humans.<sup>96</sup> Another RT-PCR assay with subsequent pyrosequencing analysis allows for a rapid, high-throughput, and cost-effective screening of subtype A/H1N1, A/H3N2, and A/H5N1 viruses and can clearly discriminate wild-type from a mutant viruses.<sup>97</sup> A study reported by Bright and colleagues<sup>98</sup> showed an alarming increase in the incidence of amantadine- and rimantadine-resistant H3N2 Flu-A viruses worldwide when the pyrosequencing technique was configured to cover a 44-base pair region of the M2 protein-encoding gene. Pyrosequencing assay capabilities were expanded to screen for 52 amino acid changes defined as avian or human specific,<sup>99</sup> and pyrosequencing-based assays recently were designed for detection and surveillance of the most commonly reported mutations associated with resistance to neuraminidase inhibitors and the adamantanes.<sup>100–106</sup> The latter detects mutations associated with resistance directly in clinical specimens, thus reducing the time required for testing and avoiding selection of novel sequence variants by cell culture. In addition, pyrosequencing-based assays have been reported for the characterization, quantification, typing, subtyping, and drug-resistance profiling of other viruses.<sup>107–112</sup>

One unique feature of pyrosequencing is its theoretical adaptability to the analysis of any genetic marker, which allows for the detection of multiple known and unknown mutations in a single pyrosequencing reaction. Integration of high-throughput pyrosequencing with the Roche/454 instrument has become a powerful tool for whole genome sequencing without the need for additional equipment or molecular techniques other than standard PCR, Genome Sequencer FLX sample preparation, and the sequencing pipeline.<sup>113</sup> Pyrosequencing generates sequence content quantitatively, which has made pyrosequencing a primary choice for quantifying specific mutations (eg,

detection of drug resistance-associated signatures) in mixed genomic populations. Because pyrosequencing byproducts inhibit the sequencing reaction, pyrosequencing read lengths are limited to less than 100 base pairs. Another drawback of pyrosequencing-based techniques includes secondary structure formation, which affects quality of the results, particularly with GC-rich targets. Additionally, it may be difficult to determine the precise number of nucleotides in a homopolymeric region based on peak heights.<sup>87</sup> It is expected that pyrosequencing-based diagnostic devices will soon become available for rapid characterization and typing of viral pathogens.

### ***Padlock Probes***

---

Padlock probes, originated by Nilsson and colleagues<sup>114</sup> in 1994, are linear oligonucleotides designed so that the two end segments, connected by a linker region, are both complementary to a target sequence. On hybridization to a target sequence, the two probe ends become juxtaposed and can be joined by a DNA ligase. Reacted probes can be detected by way of reporter molecules attached to the linker.<sup>115</sup> Alternatively, an amplified signal can be obtained from the circularized probes by rolling circle amplification. Padlock probes provide a means for detection and quantification of large numbers of DNA or RNA sequences and for highly multiplexed genetic studies.<sup>116</sup> The application of padlock probes for the detection of microbial pathogens is a recent trend in molecular diagnoses.<sup>117</sup>

The unique padlock probe design provides the benefit of speed and sensitivity derived from using a nucleic acid-based method, and the amount of information is greatly increased by extensive multiplexing. Indeed, this method was used to simultaneously detect and type 16 HA and 9 NA subtypes of avian Flu virus. The analysis is completed within approximately 4 hours and performed in a single reaction tube, which helps to decrease the risk for contamination, with just a few sequential additions of reagents before the readout is performed using an oligonucleotide array.<sup>118</sup> Padlock probes combined with back-end microarray technology have been developed to detect foot-and-mouth disease, vesicular stomatitis, and swine vesicular disease viruses.<sup>119</sup> Besides viral pathogens, padlock probe-based techniques have been rapidly extended in recent years to the identification and characterization of bacterial and fungal pathogens.<sup>120–124</sup> In addition to the applicability of padlock probes for direct target detection, a universal primer binding site can be introduced into the probe and used for MLPA (see previous discussion).

### ***Microarrays***

---

Applications of microarrays to detect and characterize respiratory viruses began with solid arrays. The first respiratory pan-viral microarray system was described in 2002, which incorporated 1600 unique 70-mer oligonucleotide probes covering approximately 140 viral genome sequences.<sup>60–65</sup> Resequencing microarrays were developed to use short oligonucleotides for the simultaneous identification of respiratory pathogens at both the species and strain level.<sup>125–127</sup> Another comprehensive and pan-microbial microarray, the GreeneChipResp system, was developed for the detection of respiratory viruses and subtype identification of Flu-A viruses.<sup>66</sup> Other recently developed solid microarray systems for detection and identification of a panel of respiratory viruses include the Infiniti analyzer, an integrated molecular diagnostic device incorporating microarray hybridization<sup>128</sup>; the electronic microarray-based Nano-chip<sup>85,129</sup>; the TaqMan Low Density Array cards, which use real-time PCR assays for 13 viruses and 8 bacteria known to cause pneumonia (Dean Erdman, 2009; personal communication); and the FilmArray, which detects and differentiates 17 viral



and 4 bacterial etiologies of respiratory tract infections (Mark Poritz, 2009; personal communication).

Suspension bead-based liquid xMAP microarrays have been developed by Luminex Corp, which are essentially three-dimensional arrays based on the use of microscopic polystyrene beads as the solid support and flow cytometry for bead and target detection.<sup>130</sup> Robust multiplexing detection is accomplished using different bead sets based on fluorescence. The system enables multiplexing of up to 100 analytes in a single reaction using small sample volumes.<sup>131,132</sup> Numerous studies have described the use of xMAP technology for the detection and differentiation of nucleic acid sequences of microbial pathogens, including enteric bacteria, viruses, mycobacteria, fungi, and protozoa.<sup>76–82,133–136</sup> A molecular typing method incorporating the suspension array was reported to characterize and type Flu-A viruses, including H5N1.<sup>83</sup> The Luminex suspension array has been incorporated into several commercial devices as the detection platform to support the laboratory differential diagnosis of common respiratory viral pathogens. These include the xTAG Respiratory Viral Panel from Luminex Molecular Diagnostics,<sup>137–139</sup> the ResPlex II assay from Qiagen,<sup>78,84,85</sup> and the MultiCode-PLx RVP assay from EraGen Biosciences.<sup>140,141</sup> The suspension array system exhibits rapid hybridization kinetics, flexibility in assay design and format, and relatively low costs, which have made it the most practical microarray platform for clinical diagnostic applications. Users should carefully determine the positive fluorescence threshold for each viral target in multiplexed, user-defined assays during validation.

### **Mass Spectrometry**

---

Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) is widely used as a powerful proteomic tool. Its rapidity and high resolution provide another powerful platform for the detection and characterization of nucleic acid amplification products. The technology is premised on the capacity of MALDI-TOF MS to discriminate individual PCR products contained in complex amplicon mixtures according to nucleotide base composition.<sup>142</sup> The deconvolution algorithm allows base composition of PCR products to be deduced from mass spectrometrically measured molecular weights and the complementary nature of DNA, leading to organism identification. Early studies successfully used this technique to directly detect amplification products from PCR<sup>143</sup> and ligase chain reaction (LCR).<sup>144</sup> Soon after, the MALDI-TOF MS platform was linked to PCR amplification for genotypic analysis of hepatitis C virus<sup>145</sup> and human papillomavirus.<sup>146,147</sup> Detection of human herpesviruses from clinical specimens was performed using MALDI-TOF MS following multiplex PCR amplification.<sup>148</sup> A MALDI-TOF MS-based genotyping assay has been described that monitors development of hepatitis B virus polymerase YMDD mutant genotypes during lamivudine treatment.<sup>149,150</sup>

An integrated system, the Ibis T5000 Biosensor, has been developed to couple broad-range nucleic acid amplification to high-performance electrospray ionization MS and base-composition analysis. The system enables the identification and quantification of a broad set of pathogens, including all known bacteria, all major groups of pathogenic fungi, and the major families of viruses that cause disease in humans and animals, along with the detection of virulence factors and antibiotic resistance markers.<sup>151</sup> The system has been used for rapid identification and strain typing of respiratory bacterial pathogens for epidemic surveillance,<sup>152</sup> identification and genotyping of *Acinetobacter baumannii* strains in an outbreak associated with war trauma,<sup>153,154</sup> determination of quinolone resistance in *Acinetobacter* species,<sup>155,156</sup> genotyping of *Campylobacter* species,<sup>155,156</sup> and rapid genotyping and clonal complex assignment of *Staphylococcus aureus* isolates.<sup>157</sup> We have used this system



Table 1

Comparison of commercially available multiplexed amplification and high-throughput systems for detection and identification of respiratory viruses

| System  | Company                                   | Viruses/Genotypes Detected  | Amplification Platform     | Detection Platform            | Characteristics  |
|---|---|---|----------------------------|-------------------------------|--|
| FimArray respiratory pathogen panel                                     | Idaho Technology Inc (Salt Lake City, UT) | AdV, bocavirus, 4 CoV, Flu-A, Flu-B, hMPV, PIV-1, PIV-2, PIV-3, PIV-4, RSV, and RhV                     | Nested multiplex RT-PCR    | Solid array analyzer          | Integrated and closed system. Also covers 4 bacterial pathogens  |
| Infiniti respiratory viral panel <sup>128</sup>                         | AutoGenomics, Inc (Carlsbad, CA)          | Flu-A, Flu-B, PIV-1, PIV-2, PIV-3, PIV-4, RSV-A, RSV-B, hMPV-A, hMPV-B, RhV-A, RhV-B, EnV, CoV, and AdV | Multiplex PCR and RT-PCR   | Infiniti solid array analyzer | Detection step by the Infiniti analyzer is completely automatic  |
| Jaguar system   | HandyLab, Inc (Detroit, MI)               | Flu-A, Flu-B, and RSV A/B   | Multiplex real-time RT-PCR | Melting temperature analysis  | Completely closed and automatic. Universal system compatible with detection of other pathogens. Throughput of 1–24 specimens/run |
| MultiCode-PLx respiratory virus panel <sup>140,141</sup>                | EraGen Biosciences (Madison, WI)          | Flu-A, Flu-B, PIV-1, PIV-2, PIV-3, PIV-4, RSV, hMPV, RhV, AdV, and CoV                                  | Multiplex PCR and RT-PCR   | Luminex suspension array      | Universal beads used for detection use EraCode sequences   |
| NGEN Respiratory Virus (RVA) Analyte-specific reagent <sup>85,129</sup> | Nanogen (San Diego, CA)                   | Flu-A, Flu-B, PIV-1, PIV-2, PIV-3, and RSV  | Multiplex RT-PCR           | NanoChip (solid chip)         | Discontinued in 2008. Probe labeling, target capture, and detection accomplished using electronic microarray technology          |

|   |   |  |                                 |                                 |  |
|---|---|--|---------------------------------|---------------------------------|--|
| ProFLU+,<br>ProPARAFLU+ <sup>161,162</sup>                  | Prodesse, Inc<br>(Waukesha, WI)                       | Flu-A, Flu-B, and RSV<br>(ProFLU+); PIV-1,<br>PIV-2, PIV-3, and<br>PIV-4 (ProPARAFLU+)           | Multiplex real-time<br>RT-PCR   | Melting temperature<br>analysis | ProFLU+ FDA cleared.<br>Limited multiplex<br>formats (triplex)   |
| ResPlex II <sup>78,84,85</sup>                              | Qiagen (Valencia, CA)                                 | Flu-A, Flu-B, PIV-1,<br>PIV-2, PIV-3, PIV-4,<br>RSV-A, RSV-B, hMPV,<br>RhV, EnV, and<br>SARS-CoV | TEM-RT-PCR                      | Luminex suspension<br>array     | Unique Tem-PCR<br>permits multiple<br>target screening in<br>single reaction<br>without significant<br>loss in sensitivity |
| Seeplex respiratory virus<br>detection assay <sup>163</sup> | Seegene, Inc (Seoul,<br>Korea)                        | AdV, hMPV, 2 CoV,<br>PIV-1, PIV-2, PIV-3,<br>Flu-A, Flu-B, RSV-A,<br>RSV-B, and RhV              | Two sets of multiplex<br>RT-PCR | Gel electrophoresis             | Dual priming<br>oligonucleotide<br>system  |
| xTAG respiratory viral<br>panel (RVP) <sup>137-139</sup>    | Luminex Molecular<br>Diagnostics (Toronto,<br>Canada) | Flu-A, Flu-B, PIV-1,<br>PIV-2, PIV-3, PIV-4,<br>RSV-A, RSV-B, hMPV,<br>AdV, EnV, CoV,<br>and RhV | Multiplex PCR and<br>RT-PCR     | Luminex suspension<br>array     | FDA cleared.<br>Target-specific primer<br>extension used in<br>combination with<br>universal detection<br>beads            |

*Abbreviations:* AdV, adenoviruses; CoV, coronaviruses; EnV, enteroviruses; Flu, influenza virus; hMPV, human metapneumovirus; PIV, parainfluenza virus; RhV, rhinoviruses; RSV, respiratory syncytial virus; TEM, target enriched multiplex.

to detect *Ehrlichia*, *Anaplasma*, and *Rickettsia* pathogens directly from blood specimens for diagnosis of tick-borne sepsis (manuscript in preparation). In the field of diagnostic virology, this strategy successfully led to the inclusion of SARS-CoV in the coronavirus family.<sup>158</sup> Furthermore, the Ibis T5000 Biosensor system has been used as a rapid and inexpensive tool for global surveillance of emerging Flu virus genotypes<sup>159</sup> and rapid detection and molecular serotyping of adenoviruses.<sup>160</sup> The system was able to detect and type all available Flu A genotypes, including recently emerged novel A/H1N1 (David Ecker, 2009; personal communication). The main advantages are high resolution, speed, and substantial degree of automation. The main disadvantages include the engineering difficulty of MS device miniaturization and need for continuous enrichment of databases with new genomic sequences.

### MULTIPLEXING AMPLIFICATION AND HIGH-THROUGHPUT DETECTION SYSTEMS

Respiratory infections caused by a many bacterial, viral, and fungal pathogens often present with overlapping signs and symptoms nearly indistinguishable by clinical diagnosis. Molecular screening of at-risk populations for a group of possible viral pathogens is an exciting area of development in molecular microbiology. Several multiplexing amplification and high-throughput detection systems are commercially available for the detection and differentiation of a panel of respiratory viral pathogens. Examples include the FilmArray platform from Idaho Technology Inc; the Infiniti Respiratory Viral Panel from AutoGenomics, Inc.<sup>128</sup>; the Jaguar system from HandyLab, Inc.; the Multi-Code-PLx respiratory virus panel from EraGen Biosciences<sup>140,141</sup>; the NGEN Respiratory Virus ASR from Nanogen<sup>85,129</sup>; the proFLU+ and the proPARA-FLU+ from Prodesse, Inc.<sup>161,162</sup>; the ResPlex II assay from Qiagen<sup>78,84,85</sup>; the Seeplex respiratory virus detection assay from Seegene, Inc.<sup>163</sup>; and the xTAG Respiratory Viral Panel from Luminex Molecular Diagnostics.<sup>137–139</sup> Some of these systems cover all varieties of Flu A genotypes including recently emerged novel A/H1N1.<sup>164</sup>

A comparative summary of these devices is presented in **Table 1**. Relative simplicity, powerful multiplexing capabilities, and affordability for high-throughput detection make these platforms most attractive for screening and detection of a panel of respiratory viruses in clinical infectious disease diagnostics. Although not essential, the availability of Food and Drug Administration–cleared products is a critical step in getting these systems into less-experienced diagnostic microbiology laboratories.<sup>4,5</sup> Opening of postamplification tubes and subsequent pipetting steps in the workflow of suspension arrays increases the risk for intra- and inter-run contamination for some assays. Careful attention should be paid to contamination control measures and the re-establishment of dedicated postamplification laboratory space in the real-time PCR era. Simultaneous testing for all possible pathogens is an efficient means to obtain a conclusive result and improves etiologic diagnosis.<sup>81,137,165</sup> In addition, assaying for all potential pathogens may yield crucial information regarding coinfections or secondary infections.<sup>84,166,167</sup> One study from the Netherlands indicated that implementation of multiple molecular assays for the etiologic diagnosis of lower respiratory tract infections increased the diagnostic yield considerably, yet did not reduce antibiotic use or costs.<sup>168</sup> Clinical relevance and cost effectiveness of simultaneous multipathogen detection and identification strategies merit further investigation.

### ACKNOWLEDGMENTS

The authors thank John Brunstein, David Ecker, Dean Erdman, Jiang Fan, and Mark Poritz for discussion, and James Chappell and Charles Stratton for reviewing the manuscript.

## REFERENCES

1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* 2003;348(20):1953–66.
2. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med* 2003;348(20):1967–76.
3. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. *N Engl J Med* 2009;360(25):2616–25.
4. Mahony JB. Detection of respiratory viruses by molecular methods. *Clin Microbiol Rev* 2008;21(4):716–47.
5. Nolte FS. Molecular diagnostics for detection of bacterial and viral pathogens in community-acquired pneumonia. *Clin Infect Dis* 2008;47(Suppl 3):S123–6.
6. Pejcić B, De Marco R, Parkinson G. The role of biosensors in the detection of emerging infectious diseases. *Analyst* 2006;131(10):1079–90.
7. Schultz JS. Sensitivity and dynamics of bioreceptor-based biosensors. *Ann N Y Acad Sci* 1987;506:406–14.
8. Malamud D, Bau H, Niedbala S, et al. Point detection of pathogens in oral samples. *Adv Dent Res* 2005;18(1):12–6.
9. Zhou X, Liu L, Hu M, et al. Detection of hepatitis B virus by piezoelectric biosensor. *J Pharm Biomed Anal* 2002;27(1–2):341–5.
10. Ju HX, Ye YK, Zhao JH, et al. Hybridization biosensor using di(2,2'-bipyridine) osmium (III) as electrochemical indicator for detection of polymerase chain reaction product of hepatitis B virus DNA. *Anal Biochem* 2003;313(2):255–61.
11. Kwakye S, Baeumner A. A microfluidic biosensor based on nucleic acid sequence recognition. *Anal Bioanal Chem* 2003;376(7):1062–8.
12. Abad-Valle P, Fernandez-Abedul MT, Costa-Garcia A. Genosensor on gold films with enzymatic electrochemical detection of a SARS virus sequence. *Biosens Bioelectron* 2005;20(11):2251–60.
13. Goldstein AN, Echer CM, Alivisatos AP. Melting in semiconductor nanocrystals. *Science* 1992;256(5062):1425–7.
14. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. *Science* 2005;307(5709):538–44.
15. Edgar R, McKinstry M, Hwang J, et al. High-sensitivity bacterial detection using biotin-tagged phage and quantum-dot nanocomplexes. *Proc Natl Acad Sci U S A* 2006;103(13):4841–5.
16. Liu WT, Zhu L, Qin QW, et al. Microfluidic device as a new platform for immunofluorescent detection of viruses. *Lab Chip* 2005;5(11):1327–30.
17. Agrawal A, Tripp RA, Anderson LJ, et al. Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes. *J Virol* 2005;79(13):8625–8.
18. Bentzen EL, House F, Utley TJ, et al. Progression of respiratory syncytial virus infection monitored by fluorescent quantum dot probes. *Nano Lett* 2005;5(4):591–5.
19. Tripp RA, Alvarez R, Anderson B, et al. Bioconjugated nanoparticle detection of respiratory syncytial virus infection. *Int J Nanomedicine* 2007;2(1):117–24.
20. Lee J, Choi Y, Kim J, et al. Positively charged compact quantum dot-DNA complexes for detection of nucleic acids. *Chemphyschem* 2009;10(5):806–11.
21. Chan P, Yuen T, Ruf F, et al. Method for multiplex cellular detection of mRNAs using quantum dot fluorescent in situ hybridization. *Nucleic Acids Res* 2005;33(18):e161.

22. Wu X, Liu H, Liu J, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. *Nat Biotechnol* 2003; 21(1):41–6.
23. Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* 2000;28(12):e63.
24. Mori Y, Nagamine K, Tomita N, et al. Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. *Biochem Biophys Res Commun* 2001;289(1):150–4.
25. Parida M, Sannarangaiah S, Dash PK, et al. Loop mediated isothermal amplification (LAMP): a new generation of innovative gene amplification technique; perspectives in clinical diagnosis of infectious diseases. *Rev Med Virol* 2008; 18(6):407–21.
26. Lakshmi V, Neeraja M, Subbalaxmi MV, et al. Clinical features and molecular diagnosis of Chikungunya fever from South India. *Clin Infect Dis* 2008;46(9): 1436–42.
27. Peyrefitte CN, Boubis L, Coudrier D, et al. Real-time reverse-transcription loop-mediated isothermal amplification for rapid detection of Rift Valley fever virus. *J Clin Microbiol* 2008;46(11):3653–9.
28. Poon LL, Leung CS, Tashiro M, et al. Rapid detection of the severe acute respiratory syndrome (SARS) coronavirus by a loop-mediated isothermal amplification assay. *Clin Chem* 2004;50(6):1050–2.
29. Poon LL, Leung CS, Chan KH, et al. Detection of human influenza A viruses by loop-mediated isothermal amplification. *J Clin Microbiol* 2005;43(1): 427–30.
30. Ito M, Watanabe M, Nakagawa N, et al. Rapid detection and typing of influenza A and B by loop-mediated isothermal amplification: comparison with immunochromatography and virus isolation. *J Virol Methods* 2006;135(2):272–5.
31. Imai M, Ninomiya A, Minekawa H, et al. Development of H5-RT-LAMP (loop-mediated isothermal amplification) system for rapid diagnosis of H5 avian influenza virus infection. *Vaccine* 2006;24(44–46):6679–82.
32. Imai M, Ninomiya A, Minekawa H, et al. Rapid diagnosis of H5N1 avian influenza virus infection by newly developed influenza H5 hemagglutinin gene-specific loop-mediated isothermal amplification method. *J Virol Methods* 2007;141(2): 173–80.
33. Jayawardena S, Cheung CY, Barr I, et al. Loop-mediated isothermal amplification for influenza A (H5N1) virus. *Emerg Infect Dis* 2007;13(6):899–901.
34. Chen HT, Zhang J, Sun DH, et al. Development of reverse transcription loop-mediated isothermal amplification for rapid detection of H9 avian influenza virus. *J Virol Methods* 2008;151(2):200–3.
35. Shirato K, Nishimura H, Saijo M, et al. Diagnosis of human respiratory syncytial virus infection using reverse transcription loop-mediated isothermal amplification. *J Virol Methods* 2007;139(1):78–84.
36. Ushio M, Yui I, Yoshida N, et al. Detection of respiratory syncytial virus genome by subgroups-A, B specific reverse transcription loop-mediated isothermal amplification (RT-LAMP). *J Med Virol* 2005;77(1):121–7.
37. Hong TC, Mai QL, Cuong DV, et al. Development and evaluation of a novel loop-mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. *J Clin Microbiol* 2004;42(5):1956–61.
38. Okafuji T, Yoshida N, Fujino M, et al. Rapid diagnostic method for detection of mumps virus genome by loop-mediated isothermal amplification. *J Clin Microbiol* 2005;43(4):1625–31.

39. Yoshida N, Fujino M, Miyata A, et al. Mumps virus reinfection is not a rare event confirmed by reverse transcription loop-mediated isothermal amplification. *J Med Virol* 2008;80(3):517–23.
40. Fujino M, Yoshida N, Yamaguchi S, et al. A simple method for the detection of measles virus genome by loop-mediated isothermal amplification (LAMP). *J Med Virol* 2005;76(3):406–13.
41. Wakabayashi T, Yamashita R, Kakita T, et al. Rapid and sensitive diagnosis of adenoviral keratoconjunctivitis by loop-mediated isothermal amplification (LAMP) method. *Curr Eye Res* 2004;28(6):445–50.
42. Schouten JP, McElgunn CJ, Waaijjer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res* 2002;30(12):e57.
43. Hsuih TC, Park YN, Zaretsky C, et al. Novel, ligation-dependent PCR assay for detection of hepatitis C in serum. *J Clin Microbiol* 1996;34(3):501–7.
44. Park YN, Abe K, Li H, et al. Detection of hepatitis C virus RNA using ligation-dependent polymerase chain reaction in formalin-fixed, paraffin-embedded liver tissues. *Am J Pathol* 1996;149(5):1485–91.
45. Bergval IL, Vijzelaar RN, Dalla Costa ER, et al. Development of multiplex assay for rapid characterization of *Mycobacterium tuberculosis*. *J Clin Microbiol* 2008;46(2):689–99.
46. Terefework Z, Pham CL, Prospero AC, et al. MLPA diagnostics of complex microbial communities: relative quantification of bacterial species in oral biofilms. *J Microbiol Methods* 2008;75(3):558–65.
47. Reijans M, Dingemans G, Klaassen CH, et al. RespiFinder: a new multiparameter test to differentially identify fifteen respiratory viruses. *J Clin Microbiol* 2008;46(4):1232–40.
48. Welsh J, McClelland M. Fingerprinting genomes using PCR with arbitrary primers. *Nucleic Acids Res* 1990;18(24):7213–8.
49. Reyes GR, Kim JP. Sequence-independent, single-primer amplification (SISPA) of complex DNA populations. *Mol Cell Probes* 1991;5(6):473–81.
50. Williams JG, Kubelik AR, Livak KJ, et al. DNA polymorphisms amplified by arbitrary primers are useful as genetic markers. *Nucleic Acids Res* 1990;18(22):6531–5.
51. Power EG. RAPD typing in microbiology—a technical review. *J Hosp Infect* 1996;34(4):247–65.
52. Winget DM, Wommack KE. Randomly amplified polymorphic DNA PCR as a tool for assessment of marine viral richness. *Appl Environ Microbiol* 2008;74(9):2612–8.
53. Harcourt BH, Tamin A, Halpin K, et al. Molecular characterization of the polymerase gene and genomic termini of Nipah virus. *Virology* 2001;287(1):192–201.
54. Afonso CL. Sequencing of avian influenza virus genomes following random amplification. *Biotechniques* 2007;43(2):188, 190, 192.
55. Ambrose HE, Clewley JP. Virus discovery by sequence-independent genome amplification. *Rev Med Virol* 2006;16(6):365–83.
56. Lambden PR, Cooke SJ, Caul EO, et al. Cloning of noncultivable human rotavirus by single primer amplification. *J Virol* 1992;66(3):1817–22.
57. Matsui SM, Kim JP, Greenberg HB, et al. The isolation and characterization of a Norwalk virus-specific cDNA. *J Clin Invest* 1991;87(4):1456–61.
58. Reyes GR, Purdy MA, Kim JP, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. *Science* 1990;247(4948):1335–9.

59. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. *Nat Med* 2001;7(6):719–24.
60. Wang D, Coscoy L, Zylberberg M, et al. Microarray-based detection and genotyping of viral pathogens. *Proc Natl Acad Sci U S A* 2002;99(24):15687–92.
61. Wang D, Urisman A, Liu YT, et al. Viral discovery and sequence recovery using DNA microarrays. *PLoS Biol* 2003;1(2):e2.
62. Chiu CY, Rouskin S, Koshy A, et al. Microarray detection of human parainfluenzavirus 4 infection associated with respiratory failure in an immunocompetent adult. *Clin Infect Dis* 2006;43(8):e71–6.
63. Urisman A, Molinaro RJ, Fischer N, et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. *PLoS Pathog* 2006;2(3):e25.
64. Chiu CY, Alizadeh AA, Rouskin S, et al. Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray. *J Clin Microbiol* 2007;45(7):2340–3.
65. Chiu CY, Greninger AL, Kanada K, et al. Identification of cardioviruses related to Theiler's murine encephalomyelitis virus in human infections. *Proc Natl Acad Sci U S A* 2008;105(37):14124–9.
66. Quan PL, Palacios G, Jabado OJ, et al. Detection of respiratory viruses and subtype identification of influenza A viruses by GreeneChipResp oligonucleotide microarray. *J Clin Microbiol* 2007;45(8):2359–64.
67. Allander T, Andreasson K, Gupta S, et al. Identification of a third human polyomavirus. *J Virol* 2007;81(8):4130–6.
68. Allander T, Emerson SU, Engle RE, et al. A virus discovery method incorporating DNase treatment and its application to the identification of two bovine parvovirus species. *Proc Natl Acad Sci U S A* 2001;98(20):11609–14.
69. Allander T, Tammi MT, Eriksson M, et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. *Proc Natl Acad Sci U S A* 2005;102(36):12891–6.
70. Djikeng A, Halpin R, Kuzmickas R, et al. Viral genome sequencing by random priming methods. *BMC Genomics* 2008;9:5.
71. Shi MM. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. *Clin Chem* 2001;47(2):164–72.
72. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. *Nat Med* 2004;10(4):368–73.
73. Braham S, Iturriza-Gomara M, Gray J. Detection of TT virus by single-primer sequence-independent amplification in multiple samples collected from an outbreak of gastroenteritis. *Arch Virol* 2009;154(6):981–5.
74. Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses identified in patients with acute viral infection syndrome. *J Virol* 2005;79(13):8230–6.
75. Jones MS, Lukashov VV, Ganac RD, et al. Discovery of a novel human picornavirus in a stool sample from a pediatric patient presenting with fever of unknown origin. *J Clin Microbiol* 2007;45(7):2144–50.
76. Han J, Swan DC, Smith SJ, et al. Simultaneous amplification and identification of 25 human papillomavirus types with Templex technology. *J Clin Microbiol* 2006;44(11):4157–62.
77. Benson R, Tondella ML, Bhatnagar J, et al. Development and evaluation of a novel multiplex PCR technology for molecular differential detection of bacterial respiratory disease pathogens. *J Clin Microbiol* 2008;46(6):2074–7.



78. Brunstein J, Thomas E. Direct screening of clinical specimens for multiple respiratory pathogens using the Genaco respiratory panels 1 and 2. *Diagn Mol Pathol* 2006;15(3):169–73.
79. Deng J, Zheng Y, Zhao R, et al. Culture versus polymerase chain reaction for the etiologic diagnosis of community-acquired pneumonia in antibiotic-pretreated pediatric patients. *Pediatr Infect Dis J* 2009;28(1):53–5.
80. Gegia M, Mdivani N, Mendes RE, et al. Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations. *Antimicrob Agents Chemother* 2008;52(2):725–9.
81. Tang YW, Kilic A, Yang Q, et al. StaphPlex system for rapid and simultaneous identification of antibiotic resistance determinants and Pantone-Valentine leukocidin detection of staphylococci from positive blood cultures. *J Clin Microbiol* 2007;45(6):1867–73.
82. Podzorski RP, Li H, Han J, et al. MVPLEX assay for direct detection of methicillin-resistant *Staphylococcus aureus* in Naris and other swab specimens. *J Clin Microbiol* 2008;46(9):3107–9.
83. Zou S, Han J, Wen L, et al. Human influenza A virus (H5N1) detection by a novel multiplex PCR typing method. *J Clin Microbiol* 2007;45(6):1889–92.
84. Brunstein JD, Cline CL, McKinney S, et al. Evidence from multiplex molecular assays for complex multipathogen interactions in acute respiratory infections. *J Clin Microbiol* 2008;46(1):97–102.
85. Li H, McCormac MA, Estes RW, et al. Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections. *J Clin Microbiol* 2007;45(7):2105–9.
86. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* 1977;74(12):5463–7.
87. Ahmadian A, Ehn M, Hober S. Pyrosequencing: history, biochemistry and future. *Clin Chim Acta* 2006;363(1–2):83–94.
88. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. *Science* 1998;281(5375):363–5.
89. Borman AM, Linton CJ, Miles SJ, et al. Molecular identification of pathogenic fungi. *J Antimicrob Chemother* 2008;61(Suppl 1):i7–12.
90. Clarke SC. Pyrosequencing: nucleotide sequencing technology with bacterial genotyping applications. *Expert Rev Mol Diagn* 2005;5(6):947–53.
91. Tenover FC. Rapid detection and identification of bacterial pathogens using novel molecular technologies: infection control and beyond. *Clin Infect Dis* 2007;44(3):418–23.
92. Pourmand N, Elahi E, Davis RW, et al. Multiplex pyrosequencing. *Nucleic Acids Res* 2002;30(7):e31.
93. Costabile M, Quach A, Ferrante A. Molecular approaches in the diagnosis of primary immunodeficiency diseases. *Hum Mutat* 2006;27(12):1163–73.
94. Lu Y, Boehm J, Nichol L, et al. Multiplex HLA-typing by pyrosequencing. *Methods Mol Biol* 2009;496:89–114.
95. Pourmand N, Diamond L, Garten R, et al. Rapid and highly informative diagnostic assay for H5N1 influenza viruses. *PLoS One* 2006;1:e95.
96. Ellis JS, Smith JW, Braham S, et al. Design and validation of an H5 TaqMan real-time one-step reverse transcription-PCR and confirmatory assays for diagnosis and verification of influenza A virus H5 infections in humans. *J Clin Microbiol* 2007;45(5):1535–43.

97. Duwe S, Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. *J Virol Methods* 2008;153(2):134–41.
98. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. *Lancet* 2005;366(9492):1175–81.
99. Waybright N, Petrangelo E, Lowary P, et al. Detection of human virulence signatures in H5N1. *J Virol Methods* 2008;154(1–2):200–5.
100. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. *JAMA* 2006;295(8):891–4.
101. Deyde VM, Nguyen T, Bright RA, et al. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. *Antimicrob Agents Chemother* 2009;53(3):1039–47.
102. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. *J Infect Dis* 2007;196(2):249–57.
103. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. *JAMA* 2009;301(10):1034–41.
104. Higgins RR, Eshaghi A, Burton L, et al. Differential patterns of amantadine-resistance in influenza A (H3N2) and (H1N1) isolates in Toronto, Canada. *J Clin Virol* 2009;44(1):91–3.
105. Lackenby A, Democratis J, Siqueira MM, et al. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. *Antivir Ther* 2008;13(6):809–20.
106. Laplante JM, Marshall SA, Shudt M, et al. Influenza antiviral resistance testing in New York and Wisconsin, 2006 to 2008: methodology and surveillance data. *J Clin Microbiol* 2009;47(5):1372–8.
107. Elahi E, Pourmand N, Chaung R, et al. Determination of hepatitis C virus genotype by pyrosequencing. *J Virol Methods* 2003;109(2):171–6.
108. Gharizadeh B, Kalantari M, Garcia CA, et al. Typing of human papillomavirus by pyrosequencing. *Lab Invest* 2001;81(5):673–9.
109. Kramski M, Meisel H, Klempa B, et al. Detection and typing of human pathogenic hantaviruses by real-time reverse transcription-PCR and pyrosequencing. *Clin Chem* 2007;53(11):1899–905.
110. O'Meara D, Wilbe K, Leitner T, et al. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. *J Clin Microbiol* 2001;39(2):464–73.
111. Rajeevan MS, Swan DC, Duncan K, et al. Quantitation of site-specific HPV 16 DNA methylation by pyrosequencing. *J Virol Methods* 2006;138(1–2):170–6.
112. Trama JP, Adelson ME, Mordechai E. Identification and genotyping of molluscum contagiosum virus from genital swab samples by real-time PCR and pyrosequencing. *J Clin Virol* 2007;40(4):325–9.
113. Hoper D, Hoffmann B, Beer M. Simple, sensitive, and swift sequencing of complete H5N1 avian influenza virus genomes. *J Clin Microbiol* 2009;47(3):674–9.
114. Nilsson M, Malmgren H, Samiotaki M, et al. Padlock probes: circularizing oligonucleotides for localized DNA detection. *Science* 1994;265(5181):2085–8.
115. Landegren U, Nilsson M. Locked on target: strategies for future gene diagnostics. *Ann Med* 1997;29(6):585–90.

116. Szemes M, Bonants P, de Weerd M, et al. Diagnostic application of padlock probes—multiplex detection of plant pathogens using universal microarrays. *Nucleic Acids Res* 2005;33(8):e70.
117. van Doorn R, Szemes M, Bonants P, et al. Quantitative multiplex detection of plant pathogens using a novel ligation probe-based system coupled with universal, high-throughput real-time PCR on OpenArrays. *BMC Genomics* 2007;8:276.
118. Gyarmati P, Conze T, Zohari S, et al. Simultaneous genotyping of all hemagglutinin and neuraminidase subtypes of avian influenza viruses by use of padlock probes. *J Clin Microbiol* 2008;46(5):1747–51.
119. Baner J, Gyarmati P, Yacoub A, et al. Microarray-based molecular detection of foot-and-mouth disease, vesicular stomatitis and swine vesicular disease viruses, using padlock probes. *J Virol Methods*. 2007;143(2):200–6.
120. Kaocharoen S, Wang B, Tsui KM, et al. Hyperbranched rolling circle amplification as a rapid and sensitive method for species identification within the *Cryptococcus* species complex. *Electrophoresis* 2008;29(15):3183–91.
121. Kong F, Tong Z, Chen X, et al. Rapid identification and differentiation of *Trichophyton* species, based on sequence polymorphisms of the ribosomal internal transcribed spacer regions, by rolling-circle amplification. *J Clin Microbiol* 2008;46(4):1192–9.
122. Tong Z, Kong F, Wang B, et al. A practical method for subtyping of *Streptococcus agalactiae* serotype III, of human origin, using rolling circle amplification. *J Microbiol Methods* 2007;70(1):39–44.
123. van Doorn R, Slawiak M, Szemes M, et al. Robust detection and identification of multiple oomycetes and fungi in environmental samples using a novel cleavable padlock probe-based ligation-detection assay. *Appl Environ Microbiol* 2009;75(12):4185–93.
124. Wamsley HL, Barbet AF. In situ detection of *Anaplasma* spp. by DNA target-primed rolling-circle amplification of a padlock probe and intracellular colocalization with immunofluorescently labeled host cell von Willebrand factor. *J Clin Microbiol* 2008;46(7):2314–9.
125. Lin B, Blaney KM, Malanoski AP, et al. Using a resequencing microarray as a multiple respiratory pathogen detection assay. *J Clin Microbiol* 2007;45(2):443–52.
126. Malanoski AP, Lin B, Wang Z, et al. Automated identification of multiple microorganisms from resequencing DNA microarrays. *Nucleic Acids Res* 2006;34(18):5300–11.
127. Wang Z, Daum LT, Vora GJ, et al. Identifying influenza viruses with resequencing microarrays. *Emerg Infect Dis* 2006;12(4):638–46.
128. Raymond F, Carbonneau J, Boucher N, et al. Comparison of automated microarray detection with real-time PCR assays for detection of respiratory viruses in specimens obtained from children. *J Clin Microbiol* 2009;47(3):743–50.
129. Takahashi H, Norman SA, Mather EL, et al. Evaluation of the NanoChip 400 system for detection of influenza A and B, respiratory syncytial, and parainfluenza viruses. *J Clin Microbiol* 2008;46(5):1724–7.
130. Horan PK, Wheeless LL Jr. Quantitative single cell analysis and sorting. *Science* 1977;198(4313):149–57.
131. Armstrong B, Stewart M, Mazumder A. Suspension arrays for high throughput, multiplexed single nucleotide polymorphism genotyping. *Cytometry* 2000;40(2):102–8.

132. Dunbar SA, Vander Zee CA, Oliver KG, et al. Quantitative, multiplexed detection of bacterial pathogens: DNA and protein applications of the Luminex LabMAP system. *J Microbiol Methods* 2003;53(2):245–52.
133. Dunbar SA, Jacobson JW. Quantitative, multiplexed detection of *Salmonella* and other pathogens by Luminex xMAP suspension array. *Methods Mol Biol* 2007; 394:1–19.
134. McNamara DT, Thomson JM, Kasehagen LJ, et al. Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. *J Clin Microbiol* 2004;42(6):2403–10.
135. Schmitt M, Bravo IG, Snijders PJ, et al. Bead-based multiplex genotyping of human papillomaviruses. *J Clin Microbiol* 2006;44(2):504–12.
136. Tarr CL, Patel JS, Pühr ND, et al. Identification of *Vibrio* isolates by a multiplex PCR assay and rpoB sequence determination. *J Clin Microbiol* 2007;45(1): 134–40.
137. Mahony J, Chong S, Merante F, et al. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. *J Clin Microbiol* 2007;45(9):2965–70.
138. Merante F, Yaghoubian S, Janeczko R. Principles of the xTAG respiratory viral panel assay (RVP Assay). *J Clin Virol* 2007;40(Suppl 1):s31–5.
139. Pabbaraju K, Tokaryk KL, Wong S, et al. Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections. *J Clin Microbiol* 2008;46(9):3056–62.
140. Lee WM, Grindle K, Pappas T, et al. High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses. *J Clin Microbiol* 2007;45(8):2626–34.
141. Nolte FS, Marshall DJ, Rasberry C, et al. MultiCode-PLx system for multiplexed detection of seventeen respiratory viruses. *J Clin Microbiol* 2007; 45(9):2779–86.
142. Muddiman DC, Anderson GA, Hofstadler SA, et al. Length and base composition of PCR-amplified nucleic acids using mass measurements from electrospray ionization mass spectrometry. *Anal Chem* 1997;69(8):1543–9.
143. Hurst GB, Doktycz MJ, Vass AA, et al. Detection of bacterial DNA polymerase chain reaction products by matrix-assisted laser desorption/ionization mass spectrometry. *Rapid Commun Mass Spectrom* 1996;10(3):377–82.
144. Jurinke C, van den Boom D, Jacob A, et al. Analysis of ligase chain reaction products via matrix-assisted laser desorption/ionization time-of-flight-mass spectrometry. *Anal Biochem* 1996;237(2):174–81.
145. Kim YJ, Kim SO, Chung HJ, et al. Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments. *Clin Chem* 2005;51(7):1123–31.
146. Hong SP, Shin SK, Lee EH, et al. High-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry. *Nat Protoc* 2008;3(9):1476–84.
147. Soderlund-Strand A, Dillner J, Carlson J. High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. *Clin Chem* 2008;54(1):86–92.
148. Sjöholm MI, Dillner J, Carlson J. Multiplex detection of human herpesviruses from archival specimens by using matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol* 2008;46(2):540–5.
149. Hong SP, Kim NK, Hwang SG, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. *J Hepatol* 2004;40(5):837–44.

150. Lee CH, Kim SO, Byun KS, et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. *Gastroenterology* 2006; 130(4):1144–52.
151. Ecker DJ, Sampath R, Massire C, et al. Ibis T5000: a universal biosensor approach for microbiology. *Nat Rev Microbiol* 2008;6(7):553–8.
152. Ecker DJ, Sampath R, Blyn LB, et al. Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance. *Proc Natl Acad Sci U S A* 2005;102(22):8012–7.
153. Ecker JA, Massire C, Hall TA, et al. Identification of *Acinetobacter* species and genotyping of *Acinetobacter baumannii* by multilocus PCR and mass spectrometry. *J Clin Microbiol* 2006;44(8):2921–32.
154. Wortmann G, Weintrob A, Barber M, et al. Genotypic evolution of *Acinetobacter baumannii* strains in an outbreak associated with war trauma. *Infect Control Hosp Epidemiol* 2008;29(6):553–5.
155. Hannis JC, Manalili SM, Hall TA, et al. High-resolution genotyping of *Campylobacter* species by use of PCR and high-throughput mass spectrometry. *J Clin Microbiol* 2008;46(4):1220–5.
156. Hujer KM, Hujer AM, Endimiani A, et al. Rapid determination of quinolone resistance in *Acinetobacter* spp. *J Clin Microbiol* 2009;47(5):1436–42.
157. Hall TA, Sampath R, Blyn LB, et al. Rapid molecular genotyping and clonal complex assignment of *Staphylococcus aureus* isolates by PCR/ESI-MS. *J Clin Microbiol* 2009;47(6):1733–61.
158. Sampath R, Hofstadler SA, Blyn LB, et al. Rapid identification of emerging pathogens: coronavirus. *Emerg Infect Dis* 2005;11(3):373–9.
159. Sampath R, Russell KL, Massire C, et al. Global surveillance of emerging Influenza virus genotypes by mass spectrometry. *PLoS One* 2007;2(5):e489.
160. Blyn LB, Hall TA, Libby B, et al. Rapid detection and molecular serotyping of adenovirus by use of PCR followed by electrospray ionization mass spectrometry. *J Clin Microbiol* 2008;46(2):644–51.
161. Legoff J, Kara R, Moulin F, et al. Evaluation of the one-step multiplex real-time reverse transcription-PCR ProFlu-1 assay for detection of influenza A and influenza B viruses and respiratory syncytial viruses in children. *J Clin Microbiol* 2008;46(2):789–91.
162. Liao RS, Tomalty LL, Majury A, et al. Comparison of viral isolation and multiplex real-time reverse transcription-PCR for confirmation of respiratory syncytial virus and influenza virus detection by antigen immunoassays. *J Clin Microbiol* 2009; 47(3):527–32.
163. Kim SR, Ki CS, Lee NY. Rapid detection and identification of 12 respiratory viruses using a dual priming oligonucleotide system-based multiplex PCR assay. *J Virol Methods* 2009;156(1–2):111–6.
164. Ginocchio CC, St George K. Likelihood that an unsubtypeable influenza A result in the Luminex xTAG respiratory virus panel is indicative of novel A/H1N1 (swine-like) influenza. *J Clin Microbiol* 2009;47(7):2347–8.
165. Templeton KE, Scheltinga SA, van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. *Clin Infect Dis* 2005;41(3):345–51.
166. Chung JY, Han TH, Kim SW, et al. Respiratory picornavirus infections in Korean children with lower respiratory tract infections. *Scand J Infect Dis* 2007;39(3): 250–4.

167. Pierangeli A, Gentile M, Di Marco P, et al. Detection and typing by molecular techniques of respiratory viruses in children hospitalized for acute respiratory infection in Rome, Italy. *J Med Virol* 2007;79(4):463–8.
168. Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. *Clin Infect Dis* 2005;41(10):1438–44.